185 related articles for article (PubMed ID: 38004528)
1. Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients.
Cura Y; Sánchez-Martín A; Márquez-Pete N; González-Flores E; Martínez-Martínez F; Pérez-Ramírez C; Jiménez-Morales A
Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004528
[TBL] [Abstract][Full Text] [Related]
2. Identification of new SNPs associated with severe toxicity to capecitabine.
Pellicer M; García-González X; García MI; Robles L; Grávalos C; García-Alfonso P; Pachón V; Longo F; Martínez V; Blanco C; Iglesias I; Sanjurjo M; López-Fernández LA
Pharmacol Res; 2017 Jun; 120():133-137. PubMed ID: 28347776
[TBL] [Abstract][Full Text] [Related]
3. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
Matsumoto N; Kubota Y; Ishida H; Sekido M; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Ikusue T; Kobayashi K; Hisamatsu A; Toshima H; Shimada K; Fujita KI
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1119-1128. PubMed ID: 32458030
[TBL] [Abstract][Full Text] [Related]
4. Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer.
Cura Y; Sánchez-Martín A; Márquez-Pete N; González-Flores E; Martínez-Martínez F; Pérez-Ramírez C; Jiménez-Morales A
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203276
[TBL] [Abstract][Full Text] [Related]
5. The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
de With M; van Doorn L; Maasland DC; Mulder TAM; Oomen-de Hoop E; Mostert B; Homs MYV; El Bouazzaoui S; Mathijssen RHJ; van Schaik RHN; Bins S
Biomed Pharmacother; 2023 Mar; 159():114232. PubMed ID: 36630849
[TBL] [Abstract][Full Text] [Related]
9. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
[TBL] [Abstract][Full Text] [Related]
10. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
[TBL] [Abstract][Full Text] [Related]
11. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
13. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Punt CJA; Heinemann V; Maughan T; Cremolini C; Van Cutsem E; McDermott R; Bodoky G; André T; Osterlund P; Teske AJ; Pfeiffer P
ESMO Open; 2023 Apr; 8(2):101199. PubMed ID: 37018874
[TBL] [Abstract][Full Text] [Related]
15. Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.
Lam SW; van der Noort V; van der Straaten T; Honkoop AH; Peters GJ; Guchelaar HJ; Boven E
Pharmacol Res; 2018 Feb; 128():122-129. PubMed ID: 28827188
[TBL] [Abstract][Full Text] [Related]
16. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Levine EL; Marschner N; Maroun J; Garcia-Alfonso P; Tujakowski J; Van Hazel G; Wong A; Zaluski J; Twelves C;
Ann Oncol; 2003 Dec; 14(12):1735-43. PubMed ID: 14630678
[TBL] [Abstract][Full Text] [Related]
17. CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy.
Liu D; Li X; Li X; Zhang M; Zhang J; Hou D; Tong Z; Dong M
Cancer Chemother Pharmacol; 2019 May; 83(5):939-949. PubMed ID: 30877365
[TBL] [Abstract][Full Text] [Related]
18. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
19. Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review.
Cura Y; Pérez-Ramírez C; Sánchez-Martín A; Membrive-Jimenez C; Valverde-Merino MI; González-Flores E; Morales AJ
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980706
[TBL] [Abstract][Full Text] [Related]
20. Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients.
van Huis-Tanja LH; Ewing E; van der Straaten RJ; Swen JJ; Baak-Pablo RF; Punt CJ; Gelderblom AJ; Guchelaar HJ
Pharmacogenet Genomics; 2015 Jun; 25(6):279-88. PubMed ID: 25815774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
